Full-Time
Enterprise Program Manager
Cronos Group
201-500 employees
Global cannabinoid company advancing research
Compensation Overview
CA$90k - CA$120k/yr
Stayner, ON, Canada
In Person
Travel domestically and internationally may be required, up to 15%.
Bachelor's
 Business & Strategy (1) |
|---|
Get referred to Cronos Group
See people who can refer or advise you
- An undergraduate degree or diploma in Life Sciences, Engineering, Business, Supply Chain, or a related field is required.
- A project management designation such as Project Management Professional, Six Sigma, or equivalent is an asset.
- Five to eight years of progressive experience in project management, product commercialization, or manufacturing operations within a regulated industry is required.
- Strong working knowledge of Good Manufacturing Practices, Good Production Practices, and European Good Manufacturing Practices frameworks is required.
- Demonstrated experience developing and executing validation plans, protocols, and reports, including Installation Qualification, Operational Qualification, and Performance Qualification, is required.
- Proven experience managing full product lifecycle projects in consumer products, pharmaceuticals, adult beverage, or similar industries.
- Cross-functional technical knowledge spanning research and development, engineering, operations, and supply chain.
- Advanced knowledge of project management methodologies, tools, and techniques; workflow process mapping, stage-gate processes, and quality management system platforms.
- Strong critical-thinking and data-analysis capabilities.
- Excellent written and verbal communication skills, including technical writing for standard operating procedures, validation documentation, and executive-level presentations.
- Demonstrated ability to inspire, direct, and develop direct and indirect teams, with experience managing and growing direct reports.
- Stakeholder-management and relationship-building skills across all levels and functions, including the ability to influence without authority.
- Strong organizational skills and adaptability in complex, fast-paced, and evolving business environments.
- Willingness to travel domestically and internationally as required, up to 15%.
- Lead multiple large, multidisciplinary projects through the full commercialization lifecycle from concept through development, regulatory review, and launch, delivering on time, on budget, and in scope.
- Build and maintain project plans covering milestones, timelines, resources, and risk mitigation.
- Own and optimize commercialization processes, tools, stage-gate frameworks, and documentation for consistent, efficient execution.
- Track milestones and escalate or adjust plans and resources to address slippage or shifting priorities.
- Manage project constraints including cost, time, scope, and quality; communicate trade-offs to stakeholders; and own commercialization inputs for stage-gate documents and business cases.
- Report progress to senior leadership, flag roadblocks, and propose solutions.
- Support capital appropriation requests for facility and production needs, including financial models and business cases.
- Serve as a Good Manufacturing Practices subject-matter expert, ensuring alignment with Health Canada Cannabis Regulations, European Good Manufacturing Practices, and market- or customer-specific standards.
- Lead the development and maintenance of Good Manufacturing Practices processes, procedures, and documentation across warehousing, processing, packaging, and quality operations.
- Assist with validation plans, protocols, and reports for equipment, utilities, cleaning, computerized systems, and manufacturing processes.
- Integrate Good Manufacturing Practices processes to support business development and expansion into new domestic and international markets.
- Guide cross-functional teams across manufacturing, engineering, quality assurance, regulatory, supply chain, research and development, sales, marketing, finance, and operations to execute plans on time and on budget.
- Give cross-functional and senior stakeholders the visibility needed to make timely decisions, allowing projects to pivot, evolve, or stop as needed.
- Hold leaders and stakeholders accountable for deliverables and timelines while maintaining collaborative partnerships and managing trade-offs.
- Build trusted relationships to leverage cross-functional expertise and serve as the central point of contact for project communications with senior and executive stakeholders.
- Communicate project updates, root-cause analyses, and risk-mitigation plans to senior leadership, providing solutions and realigning expectations as needed.
- Manage, coach, and develop direct reports and oversee hiring and onboarding as required.
- Coach and train the broader organization on Good Manufacturing Practices compliance and project-management tools, templates, and processes.
- Cannabis industry experience is an asset.
- Experience with Smartsheet is preferred.
- Knowledge of Six Sigma, statistical process control, or Lean methodologies is an asset.
Cronos Group creates and sells branded cannabis products for medical and recreational markets worldwide. It operates a portfolio of consumer brands—Spinach, PEACE NATURALS, and Lord Jones—developed through in-house cannabis research, technology and product development capabilities. Its products work by using cannabis and cannabinoid ingredients across various forms (likely oils, edibles, topical and other formats) to meet consumer preferences; the company emphasizes brand-driven offerings and quality, backed by its IP and R&D to stay ahead in a growing market. Cronos differentiates itself from competitors through a diversified brand lineup, focus on research and development, and global distribution with a strong North American and international footprint, aiming for responsible growth, industry leadership, and improved practices in cannabis supply chains.
Company Size
201-500
Company Stage
IPO
Headquarters
Toronto, Canada
Founded
2013
Get referred to Cronos Group
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $53 million, up 58% year over year.
- Spinach STIX expanded into eight provinces on May 6, 2026.
- CanAdelaar acquisition adds Dutch adult-use supply in second-half 2026.
What critics are saying
- Israel reopened anti-dumping case on August 5, 2026; duties hit PEACE NATURALS.
- Dutch regulators delayed CanAdelaar closing past June 9, 2026, showing execution drag.
- If Israel bans imports, Cronos loses its fastest-growing profit engine.
What makes Cronos Group unique
- Spinach led Canada’s vape and edible categories again in Q2 2026.
- PEACE NATURALS drove record Israeli revenue for Cronos’s tenth straight quarter.
- Cronos held $827 million cash and no debt, funding brands and deals.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Earnings season: cannabis operators deliver a different kind of Q2 2026. LOS ANGELES - The Cannabis industry wraps up its second-quarter earnings, and the aggregate picture carries a theme that would have been harder to locate a few years ago. Operators are making money. Profitability, not revenue scale, is the number that commands attention now. Cannamonitor Decide has compiled every result released through mid-August, spanning operators from Tallahassee to Tel Aviv. US msos: margins win the quarter. Among American multi-state Cannabis operators, the Q2 earnings season showed a sector holding profitability together even as top-line growth slowed. Curaleaf reported US$340 million in net revenue, up 10% year-over-year, with a 50% gross margin and US$70 million in adjusted EBITDA at a 21% margin. Green Thumb Industries posted US$307 million [approx. 5% growth] with US$84 million in normalized EBITDA at a 28% margin, though same-store sales fell 1%, partly reflecting industry-wide pricing pressure. Verano Holdings recorded US$218 million in revenue, up 8% year-over-year, while adjusted EBITDA declined to US$51 million from the prior-year period. The company completed a 1-for-5 reverse stock split during the quarter, a preparatory step toward a prospective U.S. exchange listing. Vireo Growth reported revenue of US$209.3 million for the quarter, up 335% year-over-year from $48.1 million in Q2 2025, driven by closed acquisitions. Trulieve, the first U.S. plant-touching Cannabis operator to list on the NYSE, had the most structurally layered quarter of the group. Revenue declined 10% to US$271 million, primarily reflecting the June deconsolidation of its adult-use Harvest operations, yet adjusted EBITDA reached US$98 million at a 36% margin, the highest result in the US peer set. The Curaleaf-Aurora bid. Curaleaf's Q2 results were quickly overtaken by a separate announcement. On August 11, the company publicly disclosed an unsolicited takeover bid for Aurora Cannabis, offering US$4.00 per share, a 45% premium to Aurora's 30-day volume-weighted average price, for a total consideration of approx. US$272 million. A combined entity, Curaleaf said, would operate across 17 countries with trailing 12-month revenue exceeding US$1.5 billion and pro-forma adjusted EBITDA approaching US$350 million. The company projects at least US$40 million in annual cost savings through supply chain integration, citing Aurora's 50-plus tons of annual EU-GMP cultivation capacity as the primary supply-side rationale. Curaleaf chairman and CEO Boris Jordan had initiated contact with Aurora's leadership in late June. Aurora declined to engage. By now, no formal negotiations had begun. Canadian producers pull ahead. The performance gap between US and Canadian operators was wider than many observers expected. Cronos Group reported a 58% year-over-year increase to C$53 million in net revenue; its tenth consecutive record quarter in Israel, driven by PEACE NATURALS flower demand in the Israeli medical market and Germany. Gross margin reached 54%, and the company swung to net income of US$35.7 million from a US$38.5 million net loss in the same period last year. Organigram grew revenue 49% [contribution from the April acquisition of Germany's Sanity Group], Rubicon Organics posted a record quarter, Auxly added 18%, and Canopy contributed 13% growth. International medical exposure and lighter excise structures are creating a differential the US domestic market cannot currently match. Europe's two-track quarter. Cantourage Group SE traded revenue scale for earnings quality. Q2 net revenue fell 22% year-over-year to €21.8 million, while EBITDA rose 45% to €2.9 million, lifting the EBITDA margin to 13.1%. UK and Poland drove the profitability gain. Poland's Cosma S.A. returned to profit, reporting PLN 7.3 million in revenue. Synbiotic SE went the other direction. Two CBD-facing subsidiaries [Solidmind, operator of the Hempamed brand, and Lean Labs Pharma] filed for insolvency in late July in Münster, sending Synbiotic shares down roughly 30%. CEO Daniel Kruse attributed the filings to a sharp demand contraction for CBD and hemp products starting in March 2026, compounded by ongoing regulatory ambiguity in that segment. The episode reinforces a distinction hardening across Europe. Medical-regulated Cannabis and consumer CBD are separate commercial businesses, with materially different capital and risk profiles. HCN insight. The Q2 results, read together, describe a market that has stopped reaching for revenue scale and started concentrating on cash. US operators are generating real margin on flat or declining revenue - a posture that reflects both market maturation and the pricing pressure that has persisted across state markets for several years. Canadian producers' international medical exposure, particularly in Germany and Israel, is delivering a growth rate the US domestic market cannot currently replicate, and the structural advantages of operating outside excise-heavy Canadian frameworks are clearly showing up in gross margins. The Curaleaf-Aurora bid, if it proceeds to close, would constitute one of the most notable cross-border transactions in Cannabis industry history, testing the premise that supply-chain consolidation across different regulatory jurisdictions can generate sufficient returns to justify the acquisition premium. In Europe, the divergence between medical-focused operators building toward sustained profitability and CBD-adjacent businesses absorbing unresolved regulatory uncertainty is no longer marginal. It is a defining split in how the region's Cannabis economy is taking shape. Capital moving through this sector has more quantitative clarity available today than at any prior point in its development. The Q2 2026 scoreboard gives it good reason to use that clarity carefully. The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. Highly Capitalized cover capital markets, finance, branding, marketing and everything important in between. Most of all, Highly Capitalized follow the money.
Cronos reported record second quarter results for 2026, with net revenue of $53 million, up 58% year-over-year. The cannabis company achieved gross profit of $28.5 million, representing 96% growth, and adjusted EBITDA of $13.1 million. The company's Spinach brand maintained its position as Canada's number one vape brand for the second consecutive quarter, with 10.6% market share. In edibles, Spinach held the top spot for the eighth straight quarter. Cronos Israel posted its tenth consecutive quarter of record revenue, growing 60% year-over-year. International markets outside Israel saw 88% revenue growth, driven by demand in Germany. The Israeli Trade Levies Commissioner opened an investigation into alleged dumping of medical cannabis imports from Canada. Cronos disputes the allegations and stated it will cooperate fully with the investigation. The company ended the quarter with $827 million in cash and equivalents, generating $24 million in positive operating cash flow.
Cronos Group delivered record financial results in Q2 2026, with consolidated net revenue jumping 58% year-over-year to $53 million. The cannabis company also reported record gross profit and adjusted EBITDA. The company's Spinach brand maintained its number one position in vapes and edibles in the Canadian market for multiple consecutive quarters. International revenue outside Israel surged 88% year-over-year, driven by strong demand in Germany. Cronos reported $827 million in cash and investments whilst generating $24 million in positive operating cash flow. The company is actively repurchasing shares. Its Israel operations achieved a 10th consecutive quarter of record revenue, growing 60% year-over-year. The pending acquisition of Dutch company Canatalar is progressing, though the closing has taken longer than expected due to regulatory review. Cronos faces an anti-dumping investigation in Israel regarding medical cannabis imports from Canada.
Cronos Group reported second-quarter 2026 results showing a swing to profitability with net income of US$32.09 million, compared to a net loss in the same period last year. Sales rose to US$70.6 million whilst revenue reached US$53.01 million. Basic earnings per share from continuing operations stood at US$0.09, versus a loss per share a year earlier. The cannabis company is executing a share repurchase plan of up to 18,712,918 shares or US$50 million through May 2027. Recent product launches include Spinach STIX in Canada and the Lord Jones brand in Israel. Analysts project the company could reach US$212.6 million in revenue and US$59.8 million in earnings by 2029, though bearish forecasts suggest more cautious figures of US$182.7 million and US$64.4 million respectively.
Cronos Group reports record $53 million in second-quarter revenue, net income reaches $35.7 million. Cronos Group Inc. reported record financial results for the second quarter of 2026, with net revenue reaching $53 million, an increase of 58% from $33.5 million during the same period last year. On a constant-currency basis, net revenue increased 51% year-over-year. The company said the growth was driven primarily by higher cannabis flower sales in Israel and Germany, along with increased flower and extract sales in Canada. Gross profit nearly doubled, rising 96% from $14.5 million to $28.5 million. Gross margin increased from 43% to 54%, which the company attributed to higher average selling prices, increased sales volumes and a greater share of revenue coming from Israel and other international markets that do not impose excise taxes. Cronos reported net income of $35.7 million for the quarter, compared with a net loss of $38.5 million in the second quarter of 2025. The improvement was driven by higher gross profit and foreign currency transaction gains, partially offset by increased operating expenses. Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) reached a record $13.1 million, up from $1.7 million a year earlier. Operating income totaled $7.4 million, compared with an operating loss of $5.3 million in the prior-year period. In Canada, Cronos generated $28.7 million in quarterly net revenue, up 50% year-over-year. The company's Spinach brand remained Canada's second-largest overall cannabis brand, with a national market share of 5.9%. Spinach maintained its position as the country's top-selling edible brand, with a 20.8% market share, and remained the leading vape brand for the second consecutive quarter, with a 10.6% share of the market. The company said the five best-selling vape products nationwide during the quarter were all Spinach products. Revenue in Israel increased 60% to $15 million, marking the company's 10th consecutive quarter of record revenue in the country. On a constant-currency basis, Israeli revenue grew 32%. Revenue from other countries increased 88% to $9.3 million, led by demand for Peace Naturals flower products in Germany. Cronos ended the quarter with approximately $827 million in cash, short-term investments and interest-bearing deposits. The company also repurchased 12.3 million shares during the first half of 2026. Cronos said it remains prepared to complete its pending acquisition of Netherlands-based cannabis producer CanAdelaar B.V. once regulatory approval and other closing conditions are satisfied. The company expects the acquisition to close during the second half of 2026.